Halberd Corporation (OTC: HALB) on March 29th met with five representatives from the Centers for Disease Control and Prevention (CDC). The CDC discussed Halberd’s incredible success eradicating multiple strains of antibiotic resistant bacteria and deadly Candida auris samples previously provided by the CDC. The testing conducted at Youngstown State University (YSU) by a team led by Drs. Chester Cooper and W. Gregg Sturrus. Dr. Cooper, Professor, Department of Chemical and Biological Sciences at YSU, led off the meeting.
Over the course of the previous weeks, there has been regular updates with regard to the work that Halberd Corporation had accomplished with the antibiotic resistant bacteria that had been sent to it by the Centers for Disease Control and Prevention (CDC). Last week on March 29 the company had a meeting with five representatives from the CDC.
The CDC team spoke about the significant success that the company had found by eradicating many of the antigens like E. Coli and Candida auris. Representatives from Halberd provided the CDC representatives with a track record of success in the testing that had taken place at Youngstown State University. On April 3 the company provided some of the details from the meeting. It was noted that Dr. Chester Cooper, who is a professor at the Department of Chemical and Biological Sciences at Youngstown, had led the presentation that had been done by Halberd.
However, one of the most important outcomes from the meeting was that the CDC team acknowledged the considerable success that had been achieved by Halberd Corporation and made a key commitment. It was announced that CDC was committed to sending even more samples of fungi strains and bacteria that are considered antibiotic resistant or dangerous to the company.
After testing is conducted on these additional pathogens the two parties are going to participate in a follow-up meeting. The latest development was a significant one and it remains to be seen if it leads to any major move on the Halberd stock or not.